Market Overview

Benzinga's Top Pre-Market Losers

Related HALO
Benzinga's Top Initiations
Halozyme To Open New San Francisco Office, Expects To Recruit Talent To Help Commercialize New PEGPH20 Drug
November Small Cap Pancreatic Cancer Stock News (Small Cap Network)
Related ENTR
MaxLinear and Entropic Announce Early Termination of Hart-Scott-Rodino Waiting Period for MaxLinear's Pending Acquisition of Entropic
MaxLinear Gains On Merger Deal With Entropic Communications

Halozyme Therapeutics (NASDAQ: HALO) dipped 20.68% to $6.75 in the pre-market session after the company provided update on ViroPharma Phase 2 study of subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) with recombinant human hyaluronidase.

Entropic Communications (NASDAQ: ENTR) shares fell 16.48% to $3.70 in the pre-market trading after the company reported Q2 results. Benchmark downgraded Entropic from “buy” to “hold.”

Reliv International (NASDAQ: RELV) shares dropped 15.57% to $3.09 in pre-market trading after the company posted a Q2 net loss of $214,000, versus a year-ago net income of $103,000.

NII Holdings (NASDAQ: NIHD) dipped 6.94% to $6.70 in the pre-market session on second-quarter results.

Posted-In: Top Pre-Market LosersNews Movers & Shakers Pre-Market Outlook Markets


Related Articles (ENTR + HALO)

Get Benzinga's Newsletters